ASXL1 Frameshift Mutations Drive Inferior Outcomes in CMML Without Negative Impact in MDS
Clinical Lymphoma, Myeloma and Leukemia - United States
doi 10.1016/j.clml.2016.07.122
Full Text
Open PDFAbstract
Available in full text
Date
September 1, 2016
Authors
Publisher
Elsevier BV